1. Home
  2. Product Information
  3. Ghrelin Receptor Agonist

Product Information

Ghrelin Receptor Agonist

Compound Code RQ-00000005 (Capromorelin)
Primary Target Indications
  • Frailty
  • Gastro-esophageal reflux disease (GERD)
Development Stage Phase 2 (Frailty)
Phase 1 (GERD)
Portfolio for global development, manufacturing, and marketing rights
Product Summary Ghrelin is a peptide that promotes a growth hormone secreted by the stomach and exhibits a variety of physiological effects, including the promotion of appetite, gastrointestinal tract motility and stomach acid secretion, as well as improved heart function. Capromorelin (RQ-00000005) is a ghrelin receptor agonist and, because it has been shown to increase body weight without increasing body fat and to improve motility and appetite in the elderly, it has the potential for many uses, including frailty and GERD.
Non-Confidential Materials

Capromorelin (163KB)

Licensing Status

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Facilities
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
EP4 Antagonist
Cyclooxygenase-2 (COX-2) Inhibitor
Ghrelin Receptor Agonist
5-HT4 Partial Agonist
Acid Pump Antagonist
5-HT2B Antagonist
CB2 Agonist
Motilin Receptor Agonist
Licensing
Shareholder and Investor Information
To our Shareholders and Investors
Vision, Management Principle and Culture
Corporate Governance
Stock Quotes
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Corporate Introduction Video
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics